Search
 

Best Practices in New Product Commercialization

      


Features:
 17 Info Graphics
 40 Data Graphics
 313 Metrics
 12 Best Practices


Pages/Slides: 83

Delivery Format: Online PDF Document


Download Free Excerpt


ID: 5001

Price: 

Add to Cart

Non-members: Click here for a complimentary excerpt of Best Practices in New Product Commercialization.

Study Overview
Long and costly product development cycles make it essential for pharmaceutical companies to maximize use of limited staff and resources for the development of compounds with the greatest potential market value. Leading companies are integrating commercial insights earlier and earlier into the new product development process in an effort to more quickly identify and target promising compounds, reduce development cycle time, focus resources for greatest impact and increase their potential for launching a blockbuster drug.

Best Practices, LLC conducted research for this report to identify winning strategies, structures, and best practices in early-stage product commercialization (pre-clinical, Phases I and II) and portfolio management. Best Practices also sought to clarify and codify Global Product Strategy’s placement in the corporate organizational chart to determine a best fit for the group to provide optimal support.

Executives at biopharmaceutical companies can use this research to improve early-stage decision making and enhance product design to gain an overall competitive advantage in the marketplace.

NOTE: The data in this research are segmented into two parts: the Full Benchmark Class and Large Pharma.

Key Topics

  • Early Commercialization Structure
  • Functional Involvement in Early Stage Commercialization (ESC) Activities
  • Cross-Functional and Regional Collaboration
  • Essential Employee Skills and Experience
  • Investment Decision Leaders
  • Value of Early Commercialization

Key Metrics
  • Early Stage Commercialization Organizational Structure
  • Job Title of ESC Leader
  • ESC Function by Reporting Lines
  • FTEs in ESC
  • ESC Functions
  • ESC Functions at Pre-Clinical, Phase I, Phase IIB and Phase III
  • ESC Team Meeting Frequency with Stakeholders
  • Functions Serving on Decision Committee
  • Functions that Drive Investment Decisions
Key Findings
  • Early stage groups employ fewer than 50 FTEs at 59 percent of the companies in this study. Large Pharmas have more ESC employees with 33 percent of respondents employing more than 200 FTEs.
  • Successful pharmaceutical product development demands a cross-functional approach, beginning in the pre-clinical phase.
  • Market Research involves more ESC groups at more developmental phases than any other benchmarked activity.

Methodology
This research was based on benchmark survey data from 18 pharmaceutical and biotechnology companies and in-depth executive interviews with 10 early-stage leaders from those organizations.

Industries Profiled:
Health Care; Pharmaceutical; Diagnostic; Biotech; Consumer Products

Companies Profiled:
Abbott; Allergan; Alexion Pharmaceuticals; Altus Biologics; Amgen; AstraZeneca; Bayer; Eli Lilly and Company; Genentech; GlaxoSmithKline ; Human Genome Sciences; Intervet International (part of Schering-Plough); Merck; Neurocrine Biosciences; Novartis; Shire; Teva Pharmaceutical Industries Ltd; Solvay Pharmaceuticals; Vertex Pharmaceuticals

Browse Selected Pages
Click on an image below to see the full PDF version

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call Benjamin Gregory at 919-767-9160 if you have any questions.

Related Research

Non-members: Click here to review a complimentary excerpt from "Building Best-in-Class Medical Affairs Capabilities In India – Budget and Staffing Trends in Emerging Markets" STUDY OVERVIEW Pharmac... (ID 5266)
Companies Profiled: Pfizer, LifeCell, Biocon, Biogen Idec, more ...

Price: $1200.00   Free Excerpt Available

Non-members: Click here to review a complimentary excerpt from "Building Best-in-Class Medical Affairs Capabilities In India – Structure and Challenges in Emerging Markets" STUDY OVERVIEW Pharmaceu... (ID 5261)
Companies Profiled: Pfizer, LifeCell, Biocon, Biogen Idec, more ...

Price: $1147.00   Free Excerpt Available

The economic advisability of developing fixed dose combination products can be difficult to determine owing to the many associated development and commercial challenges. Key development decisions enc... (ID 5096)
Companies Profiled: Abbott, Xanodyne Pharmaceuticals, Victory, Valeant, more ...

Price: $4100.00   Free Excerpt Available

Non-members: Click here to review a complimentary excerpt of "Pharmaceutical Early-Stage Commercialization: Structure & Functions that Lead to Success" STUDY OVERVIEW Long and costly product develo... (ID 5020)
Companies Profiled: Abbott Laboratories, Allergan, Alexion Pharmaceuticals, Altus Biologics, more ...

Price: $2598.00   Free Excerpt Available

Non-members: Click here for a complimentary excerpt of Pharmaceutical New Product Planning: Structure and Activities to Drive Growth & Profitability Study Overview Pharmaceutical and biotech compani... (ID 5008)
Companies Profiled: Abbott, Actelion, Alcon, Allergan, more ...

Price: $9000.00   Free Excerpt Available

Non-members: Click here for a complimentary excerpt of Best Practices in New Product Commercialization. Study Overview Long and costly product development cycles make it essential for pharmaceutical... (ID 5001)
Companies Profiled: Abbott, Allergan, Alexion Pharmaceuticals, Altus Biologics, more ...

Price: $4995.00   Free Excerpt Available

Study Overview To ensure future growth and profitability, companies are trying to strengthen and revitalize their brand images, refocus sales forces and streamline marketing processes... (ID 4701)
Companies Profiled: Ford Motor Company, Pepsi, DuPont, SAS Institute, more ...

Price: $539.00

Study Overview Top companies find that developing yearly business plans for all products in the development pipeline allow companies to budget all resources, thereby reducing waste and idle resources... (ID 4682)
Companies Profiled: Eli Lilly, Pfizer, Amgen, Janssen

Price: $1278.95

Based on a survey of 65 diverse organizations, this 17-slide presentation shows how global companies with multiple business units consistently organize and coordinate new product development activiti... (ID 4535)
Companies Profiled: Abbott, Janssen Cilag Pharmaceutical, Bank of Guam, Sage, more ...

Price: $604.95

This 21-page presentation profiles 20 of the top DNA technology labs. The profiles include addresses, research interests, a contact name, the type of ownership as well as a detailed description of the... (ID 4512)
Companies Profiled: Canjii, Boehringer-Ingelheim, ATP, Affymetrix, more ...

Price: $299.95

This 21-slide presentation presents results of qualitative interviews with experts from the DNA technology field who make predictions for the next 10 years... (ID 4511)
Companies Profiled: ATP, Johns Hopkins, Cal Tech, Stanford University, more ...

Price: $574.95

This 39-slide presentation includes findings and forecasting on gene maps and DNA technology... (ID 4510)
Companies Profiled: Boehringer-Ingelheim, Vysis, Stratagene, Celera, more ...

Price: $891.95


 
ACCESS AND INTELLIGENCE FOR ACHIEVING WORLD-CLASS EXCELLENCE